Dice Therapeutics

Acquired

South San Francisco, United States · Founded 2013 · $60.0M raised

Employees
51–200
Founded
2013
Business Model
B2B
Total Funding
$60.0M
Last Round
$60.0M Series BAug 2021
Rounds
2
Acquisition Date
Jun 2023

About

DICE Therapeutics was a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on discovering and developing oral small molecule therapies that target protein-protein interactions — a class of targets traditionally considered undruggable. Founded in 2013 by CEO Kevin Judice and Phil Patten, DICE developed its proprietary DC Platform to identify small molecules capable of modulating large and complex protein interfaces with high selectivity. The company was acquired by Eli Lilly in 2023.

Summary

Dice Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2013. It has raised $60.0M in total across 2 rounds, most recently a $60.0M Series B round in Aug 2021. Investors include Eli Lilly, RA Capital Management and Sands Capital.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionJun 2023
$2.4B

Sign up to see all 4 rounds

Series B through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Dice Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/dice-therapeutics"><img src="https://indexed.vc/api/badge/company/dice-therapeutics" alt="Dice Therapeutics on Indexed.vc" width="260" height="76" /></a>